Mo Elsayed, MD

Interventional Radiologist. Passionate about improving cancer treatments. 🎓 @JohnsHopkins @BrownMedicine @EmoryIrad @MSKCancerCenter

[Mo Elsayed, MD @MElsayedMD]

Metformin: A diabetes drug with FASCINATING anti-aging and anti-cancer properties. Data shows it can improve response to cancer treatments. Our new study suggests that it can enhance tumor response to Y-90 radiotherapy in HCC. Manuscript here: https://t.co/YrQ1Wwasq4

[Mo Elsayed, MD @MElsayedMD]

Agree!👏🏼💯

[Ashley Aaroe MD @AshleyAaroe]

This is part of what drives my interest in advocacy. This type of testing can be very impactful

[Society of Interventional Radiology @SIRspecialists]

#BreakingNews for #IRad!

[Mo Elsayed, MD @MElsayedMD]

Interventional radiology for dermatologic conditions? 🤔@JVIRmedia @SIR_ECS @sir

[Eric Topol @EricTopol]

New @ScienceMagazine
Discovery of a circuit that connects stress and skin inflammation
https://t.co/Dkmmcs96JT
https://t.co/chrXyKrG2N

[Eric Topol @EricTopol]

New @ScienceMagazine
Discovery of a circuit that connects stress and skin inflammation
https://t.co/Dkmmcs96JT
https://t.co/chrXyKrG2N

[Austin Bourgeois @AustinBourgeois]

Prostatic Artery Embolization vs TURP:

"All outcomes, including IPSS, QOL, peak flow, and postvoid residual volume (PVR), were equivalent at 12 and 24 months. TURP --> higher rates of bladder catheterization and hospitalization. Major complications were encountered only in the TURP group."

https://t.co/fnjDNBENmD

#iRad

[Michal Mauda-Havakuk @MichalMauda]

1/4

Exciting to share that our latest research, "Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration," has been published in Frontiers in Pharmacology >>

https://t.co/pFZvRE3hpS

[Mamadi Papus Keita, MD @MPKeitaMD]

Over 300 cases a year shared between heart transplant, lung transplant, and Heartmate 3 LVADs… here’s to another one ✈️ 🫀🫁

[Mo Elsayed, MD @MElsayedMD]

@sdamico Fantastic read. Hopefully the "Electric Stack" concept catches on so we can better focus our efforts! Thank you @sdamico @packyM

[Mo Elsayed, MD @MElsayedMD]

Fascinating approach for an all too common problem. Amazing developments happening in NeuroIR!

[JNIS @JNIS_BMJ]

Ophthalmic artery angioplasty for the treatment of age-related macular degeneration (AMD)? Lylyk et al provide a series of 17 patients with late stage AMD treated with a novel percutaneous catheter system, showing functional improvements with acceptable rates of complication. https://t.co/W8QHQzLbSq #angioplasty #AMD @pnlylyk

[Samuel Hume @DrSamuelBHume]

There's been amazing progress against liver cancer over the last 60 years

(Specifically, hepatocellular carcinoma treated with surgery)

What's driven the progress?

Earlier detection, safer and better operations, better biomarkers, and better treatment of recurrence

[Pamela Woodard, MD @PamelaWoodardp]

First United States⁩ ⁦@SiemensHealth⁩ Biograph ONE PET/MRI. Ready for installation in the Center for Clinical Imaging Research ⁦@WashUMedMIR⁩ (signed for in 2018 - well worth the wait!) ⁦

[Mo Elsayed, MD @MElsayedMD]

@Neil_Iyengar @WinshipAtEmory Welcome to GA! Congratulations 👏🏼

[Mo Elsayed, MD @MElsayedMD]

@t_intheleadcoat @farkomd @JayMathewsMD @kmadass @LessneVIR @CraigMWalkerMD @SDhandMD @keithppereira @limbsalvagedr @roblookstein @saherssabri @docTPlive @HadyLichaaMD @laronecampbell @IR_Doctor @IRKhalsa @linemonkeymd @baijazvascular @_backtable @DrJayMohan @jmills1955 Well done! What was your end point for thrombin injection while the balloon was up?

[Sean Langenfeld @SeanLangenfeld]

Important recent @AnnSurgOncol study from @WashUSurgery looking retrospectively at long-term outcomes of near-complete responses who undergo #WatchAndWait for rectal cancer.

Almost all patients received SCRT followed by consolidation chemo-->48% cCR, 28% near-complete (NCR), and 24% incomplete

The NCRs (n=61) had a median f/u of 27 months: 6.6% developed distant metastasis and 41% developed local regrowth.

The next part is important! Please keep reading!

64% of NCRs evolved into cCRs within 3-6 months. Of those, only 15% (6/39) developed local regrowth.

36% of NCRs continued to be NCRs (ulcers, nodularities, abnormal MRIs), and 86% of these (19/22) developed local regrowth.

21 patients underwent salvage surgery with 95%=R0. Unfortunately, 4/21 (19%) developed local recurrence after surgery.

What does this mean to me? Near-complete responses can evolve into cCRs in 3-6 months, and have excellent outcomes with watch-and-wait...they just needed a little more time.

However, if the irregularity remains after 3-6 months, I'm putting that rectum in a bucket.

https://t.co/Q1wpkVIfq3

[The Lancet Oncology @TheLancetOncol]

Online First:

Results from the COLLISION trial:

Thermal #ablation versus #surgical resection of small-size #ColorectalLiverMetastases: an international, randomised, controlled, phase 3 non-inferiority trial https://t.co/uQjzlVKLlO

[Mo Elsayed, MD @MElsayedMD]

@AshleyAaroe @abkhan_md @NeuroOnc @JHUAlumniAssoc @MDAndersonNews @DrJeffWeinberg @Lymphoma_Doc So cool! Congratulations @ab

[Mo Elsayed, MD @MElsayedMD]

@maxwellcoopermd @NorthwesternIR @NURadiology Well deserved huge congrats!

[Mark Lewis, MD, FASCO @marklewismd]

With a truly commendable methodology the Dutch COLLISION trial shows non-inferiority of thermal ablation to resection for small (<3cm) colorectal cancer liver metastases #ASCO24 #crcsm

https://t.co/eRLV8DgR0Y